10-K · March 18, 2026
Aclarion positions NOCISCAN as a non‑invasive, MRS‑based diagnostic to improve surgical decisioning for discogenic low back pain, targeting a $134.5B U.S. low back and neck pain market. The Company reports meaningful…
Earnings analysis · 10-Q
ACON earnings analysis
Filed May 13, 2026 · Our reading of the company's report
The latest report
Aclarion, Inc. reported a total revenue increase of 11.3% year-over-year for the first quarter of 2026, reaching $21.14 million, compared to $18.99 million in the same period last year. The company's gross margin…
Read full summary
Aclarion, Inc. reported a total revenue increase of 11.3% year-over-year for the first quarter of 2026, reaching $21.14 million, compared to $18.99 million in the same period last year. The company's gross margin improved to 17.7% from negative 23.6% due to decreased costs of revenue, although operating loss widened due to significant increases in expenses across sales, marketing, and general administration.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Gross margin
- 17.7%
What stood out
-
Revenue Growth
Revenue increased 11.3% to $21.14 million from $18.99 million YoY, driven by more NOCISCAN® reports sold.
-
Gross Margin Improvement
Gross margin improved to 17.7%, up from negative 23.6%, reflecting lower costs and favorable revenue mix.
-
Decreased Cost of Revenue
Cost of revenue decreased 25.9% to $17.39 million compared to $23.48 million in 2025.
-
Increased Interest Income
Interest income rose to $133,035 in Q1 2026 from $42,163, reflecting higher cash balances.
-
Strong Cash Position
Cash and cash equivalents totaled $19.03 million, including $25,000 of restricted cash.
-
Effective Forward Outlook
Management expects continued revenue growth as more insurance payors engage.
What to watch
-
Widening Operating Loss
Operating loss increased to $(2.99) million in Q1 2026 from $(1.49) million YoY.
-
Rising Expenses
Total operating expenses rose 101.1% to $2.99 million compared to $1.49 million last year, mainly in sales and marketing.
-
Reliance on Financing
Lower net cash provided from financing activities, $9.68 million compared to $16.89 million YoY, highlights funding dependency.
Management's outlook
Management anticipates growth in revenues as scan volumes increase.
Earlier filings 4
10-K · April 9, 2025
Aclarion (Acon) is a clinical-stage diagnostic imaging company commercializing NOCISCAN, an MRS-based software that targets the $134.5B U.S. low back and neck pain market. The 10-K emphasizes strong clinical evidence…
10-Q · August 14, 2024
Aclarion reported Q2 revenue of $10,971 and a net loss of $1,238,077 (EPS $(0.15)). Revenue declined from $17,072 in Q2 2023 to $10,971 in Q2 2024 and gross margin was deeply negative at -112.3%. The company raised…
10-Q · May 15, 2024
Aclarion reported Q1 2024 revenue of $10,114 (down from $25,470 in Q1 2023) and a net loss of $2.399M, or $(0.44) per share. Liquidity improved after the Feb 27, 2024 public offering and equity line financing (cash,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.